The chart below shows the treatment the participants took.
18 participants
- Budesonide, glycopyrronium, and formoterol fumarate combined into a single treatment
- 320 μg of budesonide
- 14.4 μg of glycopyrronium
- 9.6 μg of formoterol fumarate
- Through an inhaler
- 1 dose during the study

What happened during this study?
The study started in May 2019 and ended in March 2020. Each participant was in the study for about 6 weeks, but the entire study took 10 months to finish.

The chart below shows what happened during the study.

Before the participants took the study drugs, took the study drugs, and after the participants took the study drugs:
- 1 visit
- The study doctors checked to make sure the participants could join the study. On the second day, they took 1 dose of budesonide, glycopyrronium, and formoterol fumarate combined.
- The study doctors: 
  - Did a physical examination and checked the participants' vital signs.
  - Took urine samples.
  - Checked the participants' heart health using an electrocardiogram (ECG).
  - Checked the participants' lung health.
  - Asked the participants about their medical history, how they were feeling, and what medicines they were taking.
- Up to 1 month and 2 days after treatment.

Clinical Study Results.